Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-17
2011-05-17
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S171000
Reexamination Certificate
active
07943612
ABSTRACT:
Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPARδ and should be useful for treating conditions mediated by the same.
REFERENCES:
patent: 4920132 (1990-04-01), Huang et al.
patent: 5324743 (1994-06-01), Dillard et al.
patent: 5538768 (1996-07-01), Marden et al.
patent: 6448293 (2002-09-01), Andrews et al.
patent: 6525094 (2003-02-01), Zhang et al.
patent: 6630504 (2003-10-01), Andrews et al.
patent: 6869975 (2005-03-01), Abe et al.
patent: 6875780 (2005-04-01), Auerbach et al.
patent: 6939875 (2005-09-01), Auerbach et al.
patent: 6964983 (2005-11-01), Auerbach et al.
patent: 7244763 (2007-07-01), Bratton et al.
patent: 7816385 (2010-10-01), Sauerberg et al.
patent: 2004/0192743 (2004-09-01), Mjalli et al.
patent: 2004/0209936 (2004-10-01), Bratton et al.
patent: 2005/0113440 (2005-05-01), Auerbach et al.
patent: 2007/0082907 (2007-04-01), Canada et al.
patent: 2009/0192162 (2009-07-01), Ebdrup
patent: 2009/0209588 (2009-08-01), Havranek et al.
patent: 2279659 (1995-01-01), None
patent: 2003/171275 (2003-06-01), None
patent: WO 97/27847 (1997-08-01), None
patent: WO 97/27857 (1997-08-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/28137 (1997-08-01), None
patent: WO 97/28149 (1997-08-01), None
patent: WO 98/27974 (1998-07-01), None
patent: WO 99/04815 (1999-02-01), None
patent: WO 99/20275 (1999-04-01), None
patent: WO 01/00603 (2001-01-01), None
patent: WO 01/25181 (2001-04-01), None
patent: WO 01/25226 (2001-04-01), None
patent: WO 01/34137 (2001-05-01), None
patent: WO 01/34200 (2001-05-01), None
patent: WO 01/60807 (2001-08-01), None
patent: WO 01/66098 (2001-09-01), None
patent: WO 01/79197 (2001-10-01), None
patent: WO 02/14291 (2002-02-01), None
patent: WO 02/28434 (2002-04-01), None
patent: WO 02/46154 (2002-06-01), None
patent: WO 02/50048 (2002-06-01), None
patent: WO 02/053547 (2002-07-01), None
patent: WO 02/059098 (2002-08-01), None
patent: WO 02/062774 (2002-08-01), None
patent: WO 02/070011 (2002-09-01), None
patent: WO 02/076957 (2002-10-01), None
patent: WO 02/079162 (2002-10-01), None
patent: WO 02/080899 (2002-10-01), None
patent: WO 02/098840 (2002-12-01), None
patent: WO 02/100812 (2002-12-01), None
patent: WO 03/002081 (2003-01-01), None
patent: WO 03/016265 (2003-02-01), None
patent: WO 03/016291 (2003-02-01), None
patent: WO 03/024395 (2003-03-01), None
patent: WO 03/033453 (2003-04-01), None
patent: WO 03/033493 (2003-04-01), None
patent: WO 03/035603 (2003-05-01), None
patent: WO 03/072100 (2003-09-01), None
patent: WO 03/074050 (2003-09-01), None
patent: WO 03/074051 (2003-09-01), None
patent: WO 03/074052 (2003-09-01), None
patent: WO 03/074495 (2003-09-01), None
patent: WO 03/084916 (2003-10-01), None
patent: WO 03/097607 (2003-11-01), None
patent: WO 2004/000315 (2003-12-01), None
patent: WO 2004/000762 (2003-12-01), None
patent: WO 2004/005253 (2004-01-01), None
patent: WO 2004/007439 (2004-01-01), None
patent: WO 2004/056740 (2004-07-01), None
patent: WO 2004/060871 (2004-07-01), None
patent: WO 2004/063165 (2004-07-01), None
patent: WO 2004/063166 (2004-07-01), None
patent: WO 2004/071447 (2004-08-01), None
patent: WO 2004/073606 (2004-09-01), None
patent: WO 2004/080943 (2004-09-01), None
patent: WO 2004/080947 (2004-09-01), None
patent: WO 2004/092117 (2004-10-01), None
patent: WO 2004/093879 (2004-11-01), None
patent: WO 2004/099170 (2004-11-01), None
patent: WO 2005/054176 (2005-06-01), None
patent: WO 2005/097098 (2005-10-01), None
patent: WO 2005/097762 (2005-10-01), None
patent: WO 2005/097763 (2005-10-01), None
patent: WO 2005/105726 (2005-11-01), None
patent: WO 2005/113506 (2005-12-01), None
patent: WO 2007/003581 (2007-01-01), None
Landreth et al. Neurobiology of Aging, 2001, 22, 937-944.
Peters et al. Biochimica et Biophysica Acta 2009, 1796, 230-241.
Golub et al., Science, vol. 286, Oct. 15, 1999, pp. 531-537.
Epple et al. Bioorganic & Medicinal Chemistry Letters 2006, 16, 4376-4380.
Gross et al. Best Practice & Research Clinical Endocrinology & Metabolism 2007, 21, 687-710.
Colagiuri et al. American Journal of Public Health, Sep. 2006, vol. 96, No. 9, pp. 1562-1569.
Park Diabetes Research and Clinical Practice 66S (2004), S33-S35.
Curtis et al. The Journal of the American Board of Family Practice, vol. 18, pp. 37-43, (2005).
Hussain et al. Diabetes Research and Clinical Practice 2007, 76, 317-326.
Giron, D. J. Therm. Anal. Cal. 2001, 64, pp. 37-60.
Giron, D. J. Therm. Anal. Cal. 2002, 68, pp. 335-357.
B. Rodriquez-Spong et al. Advanced Drug Delivery Reviews, 2004, 56, pp. 241-274.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
PCT International Search Report for Application No. PCT/EP2007/052130 dated Mar. 8, 2007.
Berger et al., Journal of Biological Chemistry, vol. 274, No. 10, pp. 6718-6725 (1999).
Berger, J. and Wagner, J., “Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors,” Diabetes Technology & Therapeutics, vol. 4(2), pp. 163-174 (2002).
Byrn et al., “Solid-State Chemistry of Drugs” SSI, Inc., Chapter 11, 2nd Edition, pp. 233-248, (1999).
Chilonczyk et al., “Hypolipidaemic and antiplatelet agents”, 2001, Expert Opin. Ther. Patents, 11 (8), pp. 1301-1327.
Dressel, U. et al., Mol Endocrinol, 2003, vol. 17, Part 12, pp. 2477-2493.
Everett, L., et al., “The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease,” Liver, vol. 20, pp. 191-199 (2000).
Fruchart, J., “PPAR and Cardiovascular Risk: Overview,” J. Cardiovasc. Risk, vol. 8(4), pp. 185-186 (Aug. 2001).
Guillory, “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids” in Polymorphism in Pharmaceutical Solids, pp. 183-226 (H. G. Brittain, ed., 1999).
Havranek et al., “E/Z Isomerization of 3,3-disubstituted allylic thioethers” Tetrahedron Lett., vol. 48, pp. 6970-6973 (2007).
Holst, D. et al., Biochem Biophys Acta, 2003, vol. 1633, pp. 43-50.
Jones, B., “Peroxisome Proliferative-Activated Receptor (PPAR) Modulators: Diabetes and Beyond,” Medicinal Research Reviews, vol. 21(6), pp. 540-552 (Nov. 2001).
Kaplan, F., et al., “PPARs, Insulin Resistance and Type 2 Diabetes,” J. Cardiovasc. Risk, vol. 8(4), pp. 211-217 (Aug. 2001).
Kersten, S., et al., “Roles of PPARs in health and disease,” Nature, vol. 405, pp. 421-424 (May 2000).
Lee, C.H. et al., “PPAR-delta regulates glucose metabolism and insulin sensitivity”, Proceedings of the National Academy of Sciences of the USA, 2006, vol. 103, No. 9, pp. 3444-3449.
Lee, C-H et al., Science, 2003, vol. 32, pp. 453-457.
Leibowitz et al., FEBS Letters, vol. 473, pp. 333-336 (2000).
Liu, K., et al., “Identification of a Series of PPAR gamma/delta Dual Agonists via Solid-Phase Parallel Synthesis,” Bioorg. Med. Chem. Lett., vol. 11, pp. 2959-2962 (Nov. 2001).
Luquet, S. et al., Faseb J, 2003, vol. 17, Part 13, pp. 209-226.
Michalik, L., and Wahli, W., “Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions,” Curr. Opin. Biotechnology, vol. 10, pp. 564-570 (1999).
Miller, A., and Etgen, G., “Novel peroxisome proliferator-activated receptor ligands for type 2 diabetes and the metabolic syndrome,” Expert Opin. Investig. Drugs, vol. 12(9), pp. 1489-1500 (2003).
Mital, A., “PPARs: Nuclear Receptors for Antidiabetics,” CRIPS, vol. 3(1), pp. 5-8 (Jan.-Mar. 2002).
Muoio et al., Journal of Biological Chemistry, vol. 277, No. 29, pp. 26089-26097 (2002).
Notice of Allowance for U.S. Appl. No. 11/579,712, dated Dec. 10, 2010.
Notice of Allowance for U.S. Appl. No. 11/917,811, dated Jan. 5, 2011.
Oliver, et al., Proceedings of the Na
Anderson Rebecca L
Dailey Robert S.
High Point Pharmaceuticals, LLC
LandOfFree
Compounds that modulate PPAR activity, their preparation and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds that modulate PPAR activity, their preparation and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that modulate PPAR activity, their preparation and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2629836